TY  - JOUR
AU  - Kiss, Zoltán
AU  - Maráz, Anikó
AU  - Rokszin, György Aurél
AU  - Horváth, Zsolt
AU  - Nagy, Péter
AU  - Bajcsayné Fábián, Ibolya
AU  - Kovács, Valéria
AU  - Surján, György
AU  - Barcza, Zsófia
AU  - Kenessey, István
AU  - Wéber, András
AU  - Wittmann, István
AU  - Molnár, Gergő Attila
AU  - Gyöngyösi, Eszter
AU  - Buga, Viktória
AU  - Darida, Miklós
AU  - Szabó, Tamás G.
AU  - Karamousouli, Eugenia
AU  - Abonyi-Tóth, Zsolt
AU  - Bertókné, Tamás Renáta
AU  - Fürtős, Diána
AU  - Bogos, Krisztina
AU  - Moldvay, Judit
AU  - Gálffy, Gabriella
AU  - Tamási, Lilla
AU  - Müller, Veronika
AU  - Krasznai, Zoárd Tibor
AU  - Ostoros, Gyula
AU  - Pápai-Székely, Zsolt
AU  - Branyiczkiné, Géczy Gabriella
AU  - Hilbert, Lászlóné
AU  - Polgár, Csaba
AU  - Vokó, Zoltán
TI  - Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database
JF  - FRONTIERS IN ONCOLOGY
J2  - FRONT ONCOL
VL  - 15
PY  - 2025
PG  - 13
SN  - 2234-943X
DO  - 10.3389/fonc.2025.1446611
UR  - https://m2.mtmt.hu/api/publication/36073652
ID  - 36073652
N1  - * Megosztott szerzőség
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Kiss, Zoltán
AU  - Berki, Tamás
AU  - Maráz, Anikó
AU  - Horváth, Zsolt
AU  - Nagy, Péter
AU  - Bajcsayné Fábián, Ibolya
AU  - Kovács, Valéria
AU  - Rokszin, György Aurél
AU  - Surján, György
AU  - Barcza, Zsófia
AU  - Kenessey, István
AU  - Wéber, András
AU  - Wittmann, István
AU  - Molnár, Gergő Attila
AU  - Szabó, Tamás G
AU  - Buga, Viktória
AU  - Karamousouli, Eugenia
AU  - Darida, Miklós
AU  - Abonyi-Tóth, Zsolt
AU  - Bertókné Tamás, Renáta
AU  - Fürtős, Viktória Diána
AU  - Bogos, Krisztina
AU  - Moldvay, Judit
AU  - Gálffy, Gabriella
AU  - Tamási, Lilla
AU  - Müller, Veronika
AU  - Krasznai, Zoárd Tibor
AU  - Ostoros, Gyula
AU  - Pápai-Székely, Zsolt
AU  - Branyiczkiné, Géczy Gabriella
AU  - Hilbert, Lászlóné
AU  - Polgár, Csaba
AU  - Vokó, Zoltán
TI  - Overall Survival of Hungarian Cancer Patients Diagnosed Between 2011 and 2019, Based on the Health Insurance Fund Database
JF  - CANCERS
J2  - CANCERS
VL  - 17
PY  - 2025
IS  - 10
PG  - 20
SN  - 2072-6694
DO  - 10.3390/cancers17101670
UR  - https://m2.mtmt.hu/api/publication/36125308
ID  - 36125308
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Megyesfalvi, Zsolt
AU  - Gay, Carl M
AU  - Popper, Helmut
AU  - Pirker, Robert
AU  - Ostoros, Gyula
AU  - Heeke, Simon
AU  - Lang, Christian
AU  - Hoetzenecker, Konrad
AU  - Schwendenwein, Anna
AU  - Boettiger, Kristiina
AU  - Bunn, Paul A
AU  - Rényi-Vámos, Ferenc István
AU  - Schelch, Karin
AU  - Prosch, Helmut
AU  - Byers, Lauren A
AU  - Hirsch, Fred R
AU  - Döme, Balázs
TI  - Clinical insights into small cell lung cancer. Tumor heterogeneity, diagnosis, therapy, and future directions.
TS  - Tumor heterogeneity, diagnosis, therapy, and future directions.
JF  - CA-A CANCER JOURNAL FOR CLINICIANS
J2  - CA-CANCER J CLIN
VL  - 73
PY  - 2023
IS  - 6
SP  - 620
EP  - 652
PG  - 33
SN  - 0007-9235
DO  - 10.3322/caac.21785
UR  - https://m2.mtmt.hu/api/publication/34024285
ID  - 34024285
N1  - Funding Agency and Grant Number: Hungarian National Research, Development, and Innovation Office [KH130356, 2020-1.1.6-JOVO, TKP2021-EGA-33, FK-143751]; Austrian Science Fund [T 1062-B33, FWF I4677, 2020]; New National Excellence Program of the Ministry for Innovation and Technology of Hungary [UNKP-20-3, UNKP-21-3]; Hungarian Respiratory Society; International Association for the Study of Lung Cancer/International Lung Cancer Foundation Young Investigator Grant; City of Vienna Fund for Innovative Interdisciplinary Cancer Research; International Association for the Study of Lung Cancer Early Career Education Award; American Society of Clinical Oncology Young Investigator Award; Cancer Research Prevention Institute of Texas Early Clinical Investigator Award; LUNGevity Foundation Career Development Award;  [FWF I3522];  [FWF I3977]
AB  - Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit neuroendocrine features, an important subset of tumors lacks these properties. Genomic profiling of SCLC reveals genetic instability, almost universal inactivation of the tumor suppressor genes TP53 and RB1, and a high mutation burden. Because of early metastasis, only a small fraction of patients are amenable to curative-intent lung resection, and these individuals require adjuvant platinum-etoposide chemotherapy. Therefore, the vast majority of patients are currently being treated with chemoradiation with or without immunotherapy. In patients with disease confined to the chest, standard therapy includes thoracic radiotherapy and concurrent platinum-etoposide chemotherapy. Patients with metastatic (extensive-stage) disease are treated with a combination of platinum-etoposide chemotherapy plus immunotherapy with an anti-programmed death-ligand 1 monoclonal antibody. Although SCLC is initially very responsive to platinum-based chemotherapy, these responses are transient because of the development of drug resistance. In recent years, the authors have witnessed an accelerating pace of biologic insights into the disease, leading to the redefinition of the SCLC classification scheme. This emerging knowledge of SCLC molecular subtypes has the potential to define unique therapeutic vulnerabilities. Synthesizing these new discoveries with the current knowledge of SCLC biology and clinical management may lead to unprecedented advances in SCLC patient care. Here, the authors present an overview of multimodal clinical approaches in SCLC, with a special focus on illuminating how recent advancements in SCLC research could accelerate clinical development.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Heymach, John V.
AU  - Harpole, David
AU  - Mitsudomi, Tetsuya
AU  - Taube, Janis M.
AU  - Gálffy, Gabriella
AU  - Hochmair, Maximilian
AU  - Winder, Thomas
AU  - Zukov, Ruslan
AU  - Garbaos, Gabriel
AU  - Gao, Shugeng
AU  - Kuroda, Hiroaki
AU  - Ostoros, Gyula
AU  - Tran, Tho V.
AU  - You, Jian
AU  - Lee, Kang-Yun
AU  - Antonuzzo, Lorenzo
AU  - Papai-Szekely, Zsolt
AU  - Akamatsu, Hiroaki
AU  - Biswas, Bivas
AU  - Spira, Alexander
AU  - Crawford, Jeffrey
AU  - Le, Ha T.
AU  - Aperghis, Mike
AU  - Doherty, Gary J.
AU  - Mann, Helen
AU  - Fouad, Tamer M.
AU  - Reck, Martin
TI  - Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
JF  - NEW ENGLAND JOURNAL OF MEDICINE
J2  - NEW ENGL J MED
VL  - 389
PY  - 2023
IS  - 18
SP  - 1672
EP  - 1684
PG  - 13
SN  - 0028-4793
DO  - 10.1056/NEJMoa2304875
UR  - https://m2.mtmt.hu/api/publication/34310821
ID  - 34310821
AB  - Background Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to improve long-term outcomes.Methods We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual) to receive platinum-based chemotherapy plus durvalumab or placebo administered intravenously every 3 weeks for 4 cycles before surgery, followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. Randomization was stratified according to disease stage (II or III) and programmed death ligand 1 (PD-L1) expression (>= 1% or <1%). Primary end points were event-free survival (defined as the time to the earliest occurrence of progressive disease that precluded surgery or prevented completion of surgery, disease recurrence [assessed in a blinded fashion by independent central review], or death from any cause) and pathological complete response (evaluated centrally).Results A total of 802 patients were randomly assigned to receive durvalumab (400 patients) or placebo (402 patients). The duration of event-free survival was significantly longer with durvalumab than with placebo; the stratified hazard ratio for disease progression, recurrence, or death was 0.68 (95% confidence interval [CI], 0.53 to 0.88; P=0.004) at the first interim analysis. At the 12-month landmark analysis, event-free survival was observed in 73.4% of the patients who received durvalumab (95% CI, 67.9 to 78.1), as compared with 64.5% of the patients who received placebo (95% CI, 58.8 to 69.6). The incidence of pathological complete response was significantly greater with durvalumab than with placebo (17.2% vs. 4.3% at the final analysis; difference, 13.0 percentage points; 95% CI, 8.7 to 17.6; P<0.001 at interim analysis of data from 402 patients). Event-free survival and pathological complete response benefit were observed regardless of stage and PD-L1 expression. Adverse events of maximum grade 3 or 4 occurred in 42.4% of patients with durvalumab and in 43.2% with placebo. Data from 62 patients with documented EGFR or ALK alterations were excluded from the efficacy analyses in the modified intention-to-treat population.Conclusions In patients with resectable NSCLC, perioperative durvalumab plus neoadjuvant chemotherapy was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone, with a safety profile that was consistent with the individual agents. (Funded by AstraZeneca; AEGEAN ClinicalTrials.gov number, NCT03800134.)
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Ostoros, Gyula
AU  - Hettle, Robert
AU  - Georgoulia, Nefeli
AU  - Berktas, Mehmet
AU  - Chander, Pratibha
AU  - Diaz Perez, Ignacio
AU  - Couto, Anne-Marie
AU  - Eichinger, Christian
AU  - Field, Polly
AU  - Morten, Peter
TI  - Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis
JF  - EXPERT REVIEW OF ANTICANCER THERAPY
J2  - EXPERT REV ANTICANC
VL  - 23
PY  - 2023
IS  - 12
SP  - 1305
EP  - 1313
PG  - 9
SN  - 1473-7140
DO  - 10.1080/14737140.2023.2272645
UR  - https://m2.mtmt.hu/api/publication/36063902
ID  - 36063902
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bogos, Krisztina
AU  - Török, Szilvia
AU  - Pucsok, Mariann
AU  - Cselkó, Zsuzsa
AU  - Rényi-Vámos, Ferenc István
AU  - Ostoros, Gyula
AU  - Döme, Balázs
AU  - Megyesfalvi, Zsolt
TI  - Covid-19-fertőzés klinikai jelentősége tüdőrák és egyéb malignus mellkasi daganatok esetén
JF  - MAGYAR ONKOLÓGIA
J2  - MAGYAR ONKOLÓGIA
VL  - 66
PY  - 2022
IS  - 1
SP  - 43
EP  - 49
PG  - 7
SN  - 0025-0244
UR  - https://m2.mtmt.hu/api/publication/32773913
ID  - 32773913
N1  - Megosztott utolsó szerzők: Döme Balázs, Megyesfalvi Zsolt
AB  - The COVID-19 pandemic has posed significant challenges to healthcare systems worldwide. Patients with cancer, and particularly those with lung malignancies, represent a highrisk group for COVID-19 since they are more susceptible to infection and have a higher risk of severe outcomes. However, the restructuration of the healthcare environment, the development of guidelines for treatment and surveillance, and the improvement of vaccination coverage allowed adequate patient shielding and continuity of oncological care of cancer patients. By shedding light on the characteristics of COVID-19 patients with thoracic malignancies, recent studies also contributed to the development of personalized therapeutic strategies. Accordingly, several determinants were identified to predict disease outcomes. These include the ECOG performance status, the levels of C-reactive protein, neutrophils and procalcitonin, the disease stage, and the presence of pneumonia. COVID-19 vaccines are safe in patients with lung cancer. In order to obtain adequate immunization, the booster dose is recommended in these patients.
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Tamási, Lilla
AU  - Horváth, Krisztián
AU  - Kiss, Zoltán
AU  - Bogos, Krisztina
AU  - Ostoros, Gyula
AU  - Müller, Veronika
AU  - Urbán, László
AU  - Bittner, Nóra
AU  - Sárosi, Veronika
AU  - Vastag, Aladár
AU  - Polányi, Zoltán
AU  - Nagy-Erdei, Zsófia
AU  - Daniel, Andrea
AU  - Nagy, Balázs
AU  - Rokszin, György Aurél
AU  - Abonyi-Tóth, Zsolt
AU  - Moldvay, Judit
AU  - Vokó, Zoltán
AU  - Gálffy, Gabriella
TI  - Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016
JF  - PATHOLOGY AND ONCOLOGY RESEARCH
J2  - PATHOL ONCOL RES
VL  - 27
PY  - 2021
PG  - 9
SN  - 1219-4956
DO  - 10.3389/pore.2021.598862
UR  - https://m2.mtmt.hu/api/publication/31995461
ID  - 31995461
N1  - * Megosztott szerzőség
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bogos, Krisztina
AU  - Gálffy, Gabriella
AU  - Kiss, Z.
AU  - Tamási, Lilla
AU  - Ostoros, Gyula
AU  - Müller, Veronika
AU  - Urbán, László
AU  - Bittner, Nóra
AU  - Sárosi, Veronika
AU  - Vastag, A.
AU  - Polanyi, Z.
AU  - Daniel, A.
AU  - Nagy, Balázs
AU  - Rokszin, G.
AU  - Abonyi-Tóth, Zsolt
AU  - Barcza, Z.
AU  - Moldvay, Judit
AU  - Vokó, Zoltán
TI  - Analysis of lung cancer patient pathway: A 6-year nationwide analysis from Hungary
JF  - JOURNAL OF THORACIC ONCOLOGY
J2  - J THORAC ONCOL
VL  - 16
PY  - 2021
IS  - 4
SP  - S718
EP  - S718
PG  - 1
SN  - 1556-0864
UR  - https://m2.mtmt.hu/api/publication/31997319
ID  - 31997319
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bogos, Krisztina
AU  - Kiss, Zoltan
AU  - Tamási, Lilla
AU  - Ostoros, Gyula
AU  - Müller, Veronika
AU  - Urbán, László
AU  - Bittner, Nóra
AU  - Sárosi, Veronika
AU  - Vastag, Aladar
AU  - Polanyi, Zoltan
AU  - Nagy-Erdei, Zsofia
AU  - Daniel, Andrea
AU  - Vokó, Zoltán
AU  - Nagy, Balázs
AU  - Horvath, Krisztian
AU  - Rokszin, György Aurél
AU  - Abonyi-Tóth, Zsolt
AU  - Barcza, Zsofia
AU  - Gálffy, Gabriella
AU  - Moldvay, Judit
TI  - Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016
JF  - PATHOLOGY AND ONCOLOGY RESEARCH
J2  - PATHOL ONCOL RES
VL  - 27
PY  - 2021
PG  - 9
SN  - 1219-4956
DO  - 10.3389/pore.2021.603937
UR  - https://m2.mtmt.hu/api/publication/32037582
ID  - 32037582
AB  - Objective: Lung cancer is one of the most common cancers worldwide and its survival is still poor. The objective of our study was to estimate long-term survival of Hungarian lung cancer patients at first time based on a nationwide review of the National Health Insurance Fund database. Methods: Our retrospective, longitudinal study included patients aged >= 20 years who were diagnosed with lung cancer (ICD-10 C34) between January 1, 2011 and December 31, 2016. Survival rates were evaluated by year of diagnosis, patient gender and age, and morphology of lung cancer. Results: 41,854 newly diagnosed lung cancer patients were recorded. Mean age at diagnosis varied between 64.7 and 65.9 years during study period. One- and 5-year overall survival rates for the total population were 42.2 and 17.9%, respectively. Survival was statistically associated with gender, age and type of lung cancer. Female patients (n = 16,362) had 23% better survival (HR: 0.77, 95% confidence interval (CI): 0.75-0.79; p < 0.001) than males (n = 25,492). The highest survival rates were found in the 20-49 age cohort (5Y = 31.3%) and if the cancer type was adenocarcinoma (5Y = 20.5%). We measured 5.3% improvement (9.2% adjusted) in lung cancer survival comparing the period 2015-2016 to 2011-2012 (HR: 0.95 95% CI: 0.92-0.97; p = 0.003), the highest at females <60 year (0.86 (adjusted HR was 0.79), interaction analysis was significant for age and histology types. Conclusion: Our study provided long-term Lung cancer survival data in Hungary for the first time. We found a 5.3% improvement in 5-year survival in 4 years. Women and young patients had better survival. Survival rates were comparable to-and at the higher end of-rates registered in other East-Central European countries (7.7%-15.7%).
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - de, Marinis F.
AU  - Laktionov, K.K.
AU  - Poltoratskiy, A.
AU  - Egorova, I.
AU  - Hochmair, M.
AU  - Passaro, A.
AU  - Migliorino, M.R.
AU  - Metro, G.
AU  - Gottfried, M.
AU  - Tsoi, D.
AU  - Ostoros, Gyula
AU  - Rizzato, S.
AU  - Mukhametshina, G.Z.
AU  - Schumacher, M.
AU  - Novello, S.
AU  - Dziadziuszko, R.
AU  - Tang, W.
AU  - Clementi, L.
AU  - Cseh, A.
AU  - Kowalski, D.
TI  - Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
JF  - LUNG CANCER
J2  - LUNG CANCER-J IASLC
VL  - 152
PY  - 2021
SP  - 127
EP  - 134
PG  - 8
SN  - 0169-5002
DO  - 10.1016/j.lungcan.2020.12.011
UR  - https://m2.mtmt.hu/api/publication/32172360
ID  - 32172360
N1  - Cited By :1            
            Export Date: 2 September 2021
LA  - English
DB  - MTMT
ER  -